Clinical Study of Bivalirudin for Percutaneous Coronary Intervention (PCI)
Status:
Unknown status
Trial end date:
2020-08-12
Target enrollment:
Participant gender:
Summary
Bivalirudin is widely used as an anticoagulant to reduce the risk of bleeding in PCI
perioperative period. Additionally, 15.7%-32.7% patients have diabetes mellitus who undergo
percutaneous coronary interventions (PCI), so bivalirudin was used to anticoagulate in these
patients to evaluate its safety and efficacy.